A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II.

被引：0
|
作者：
Sieper, Joachim [1 ]
Lenaerts, Jan [2 ]
Wollenhaupt, Juergen [3 ]
Mazurov, Vadim [4 ]
Myasoutova, L. [5 ]
Park, Sung-Hwan [6 ]
Song, Yeong W. [7 ]
Yao, Ruji [8 ]
Chitkara, Denesh [8 ]
Vastesaeger, Nathan [9 ]
机构：
[1] Univ Med Berlin, Charite, Berlin, Germany
[2] Reuma Inst, Hasselt, Belgium
[3] Schon Klin, Hamburg, Germany
[4] St Petersburg Med Acad, St Petersburg, Russia
[5] Kazan State Med Univ, Kazan, Russia
[6] Catholic Univ Korea, Seoul, South Korea
[7] Seoul Natl Univ, Seoul, South Korea
[8] Merck Sharp & Dohme Ltd, Kenilworth, NJ USA
[9] Merck Sharp & Dohme Ltd, Brussels, Belgium
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
549
引用
收藏
页码：S239 / S239
页数：1
相关论文
共 50 条
  • [1] A RANDOMIZED, OPEN-LABEL STUDY TO EXPLORE WHETHER PARTIAL REMISSION CAN BE MAINTAINED WITH NAPROXEN OR NO TREATMENT IN PATIENTS WITH EARLY, ACTIVE AXIAL SPONDYLOARTHRITIS: INFAST PART II
    Sieper, J.
    Lenaerts, J.
    Wollenhaupt, J.
    Mazurov, V., I
    Myasoutova, L.
    Park, S.
    Song, Y.
    Yao, R.
    Chitkara, D.
    Vastesaeger, N.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : 640 - 640
  • [2] A RANDOMIZED, OPEN-LABEL STUDY TO EXPLORE WHETHER PARTIAL REMISSION CAN BE MAINTAINED WITH NAPROXEN OR NO TREATMENT IN PATIENTS WITH EARLY, ACTIVE AXIAL SPONDYLOARTHRITIS: PRELIMINARY RESULTS OF INFAST PART II
    Sieper, J.
    Lenaerts, J.
    Wollenhaupt, J.
    Mazurov, V. I.
    Myasoutova, L.
    Park, S. -H.
    Song, Y. -W.
    Yao, R.
    Chitkara, D.
    Vastesaeger, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 248 - 249
  • [3] Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
    Poddubnyy, Denis
    Listing, Joachim
    Sieper, Joachim
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68 (08) : 1899 - 1903
  • [4] Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2
    Sieper, J.
    Lenaerts, J.
    Wollenhaupt, J.
    Rudwaleit, M.
    Mazurov, V. I.
    Myasoutova, L.
    Park, S.
    Song, Y.
    Yao, R.
    Chitkara, D.
    Vastesaeger, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 108 - 113
  • [5] Double-Blind, Placebo-Controlled, 28-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I
    Sieper, Joachim
    Lenaerts, Jan
    Wollenhaupt, Juergen
    Mazurov, Vadim
    Myasoutova, L.
    Park, Sung-Hwan
    Song, Yeong W.
    Yao, Ruji
    Chitkara, Denesh
    Vastesaeger, Nathan
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S588 - S589
  • [6] Changes in Active Inflammatory Lesions Assessed by Magnetic Resonance Imaging: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial
    Sieper, Joachim
    Lenaerts, Jan
    Wollenhaupt, Juergen
    Mazurov, Vadim
    Myasoutova, L.
    Park, Sung-Hwan
    Song, Yeong W.
    Yao, Ruji
    Chitkara, Denesh
    Vastesaeger, Nathan
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S338 - S338
  • [7] DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EFFICACY AND SAFETY OF INFLIXIMAB+ NAPROXEN VS. NAPROXEN IN PATIENTS WITH EARLY, ACTIVE AXIAL SPONDYLOARTHRITIS TREATED WITH SUBMAXIMAL NSAIDS: INFAST PART I
    Sieper, J.
    Lenaerts, J.
    Wollenhaupt, J.
    Mazurov, V., I
    Myasoutova, L.
    Park, S.
    Song, Y.
    Yao, R.
    Chitkara, D.
    Vastesaeger, N.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : 639 - 640
  • [8] PREDICTORS OF REMISSION MAINTENANCE AND SUCCESSFUL THERAPY DISCONTINUATION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA) WHO ACHIEVED SUSTAINED REMISSION ON OPEN-LABEL ADALIMUMAB (ADA) TREATMENT
    Sieper, J.
    Landewe, R.
    Magrey, M.
    Anderson, J.
    Zhong, S.
    Wang, X.
    Lertratanakul, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 995 - 995
  • [9] Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
    Sieper, J.
    Lenaerts, J.
    Wollenhaupt, J.
    Rudwaleit, M.
    Mazurov, V. I.
    Myasoutova, L.
    Park, S.
    Song, Y.
    Yao, R.
    Chitkara, D.
    Vastesaeger, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 101 - 107
  • [10] DOUBLE-BLIND, PLACEBO-CONTROLLED, 28-WEEK TRIAL OF EFFICACY AND SAFETY OF INFLIXIMAB PLUS NAPROXEN VS NAPROXEN ALONE IN PATIENTS WITH EARLY, ACTIVE AXIAL SPONDYLOARTHRITIS TREATED WITH A SUBMAXIMAL DOSE OF NSAIDS: PRELIMINARY RESULTS OF INFAST PART I
    Sieper, J.
    Lenaerts, J.
    Wollenhaupt, J.
    Mazurov, V. I.
    Myasoutova, L.
    Park, S. -H.
    Song, Y. -W.
    Yao, R.
    Chitkara, D.
    Vastesaeger, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 247 - 248
12345